Transgene Biotek: Reg 32(1) on deviation statement not applicable for Q4 FY26

Transgene Biotek Ltd. announced that Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the Statement of Deviation or Variation, is not applicable for the quarter ended March 31, 2026. This is due to the absence of any public issue, rights issue, or preferential issue during the reporting quarter. The company referenced SEBI circular CIR/CFD/CMD1/162/2019, which specifies the requirement for such a statement only when proceeds from these issues exist. The company also noted a technical issue preventing XBRL filing for NIL entries.